UroGen Pharma Ltd. URGN

Updated: 18 Jun 2026

NASDAQ | Biotech | Biopharmaceuticals and uro-oncology treatments

No signal published yet

We already track UroGen Pharma and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.

Follow UroGen Pharma free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

Free
No email, no account, no signup.
Exchange
NASDAQ
Type
Biotech
Sector
Biopharmaceuticals and uro-oncology treatments
We're already tracking UroGen Pharma Ltd. — here are the latest events we've registered

Recent News

  • In June 2026, UroGen settled patent litigation with Teva Pharmaceuticals regarding JELMYTO, granting a generic license starting in 2030. The company reported Q1 2026 revenue of $50.9 million, significantly driven by the launch of ZUSDURI. On June 18, 2026, the stock reached a 52-week high following positive durability data from its Phase 3 trials.

What Firelda Watch includes for UroGen Pharma Ltd.

Add the company to your watchlist and get all of this automatically.

  • Free: 3 companies on your watchlist
  • Change history and monitoring for every company you follow
  • Sunday weekly brief — a short weekly roundup
  • Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of UroGen Pharma Ltd. will be delivered in the same format.

Sample analyses in the same sector

Sample full analysis — same format your watchlist gets

Boozt AB (publ)
BOOZT
HOLD
Vitrolife AB (publ)
VITR
HOLD
Lagercrantz Group
LAGR B
NEUTRAL
Tetra Tech, Inc.
TTEK
HOLD
Vicore Pharma Holding AB (publ)
VICO
HOLD

Biotech

More companies in this sector

Want to follow UroGen Pharma Ltd.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.

Follow UroGen Pharma free Follow free

Email when we publish a signal or something material happens · Sunday weekly brief

No card · No time limit on free tier · Upgrade when you need more

UroGen Pharma Ltd. URGN
UroGen Pharma — follow and we'll monitor it
Follow UroGen Pharma free Follow free
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.